3 Houston innovators to know this week

Who's who

This week's batch of innovators have had to be pretty creative in their industries. Courtesy photos

The ability to innovate lives in one's ability to think outside of the box — no matter the industry. This week's Houston innovators to know have had to get creative and think of new ways of doing things, from retailing to creating greeting cards.

Harvin Moore, president of Houston Exponential

Harvin Moore, who has a 20-year career in tech and innovation, has been named as president of Houston Exponential. Courtesy of HX

Harvin Moore has been a banker, an educator, an elected official, and more — but his newest title is president of Houston Exponential, which suits him just fine.

Now, under his new role, he's leading the nonprofit that's focused on connecting, promoting, and attracting within Houston's innovation ecosystem.

"There's no question that five years from now, or 10 years from now, Houston will be a very large and continually rapidly growing tech economy," Moore tells InnovationMap. "The question is just how fast it is going to get here." Read more.

Alex Kurkowski, founder of Tellinga

Alex Kurkowski wanted to tell a better story. Courtesy of Tellinga

Alex Kurkowski has a problem with traditional greeting cards.

"They're templated. They're frozen, stagnant, fixed in what they are," Kurkowski says. "They suck."

The Rice University MBA grad decided he would do something about it. He created his business, Tellinga — short for "telling a story" — to create a new avenue for people to communicate a message to their loved ones. Kurkowski has big plans for his company and the platform he's creating. Read more.

Steve Scala, executive vice president of corporate development for DiCentral

Steve Scala joined DiCentral in 2014 to focus on growing the company worldwide. Courtesy of DiCentral

Something's brewing in retail — and it's scaring the industry. Steve Scala writes in a guest column for InnovationMap that dropshipping — the process of shipping products direct from vendors to customers, cutting out warehouses and storage facilities — is only going to gain traction in the industry.

"The study found that approximately 88 percent of retailers see dropship as inevitable to long-term success," Scala writes. "According to 87 percent of those retailers surveyed also experienced an increase in revenue as a result of dropshipping. Customer service also benefitted from dropship, with 84 percent of retailers noting improvements to customer service after adopting the dropshipping fulfillment model." Read more.

Tellinga creates artistic and personal cards for every occasion. Courtesy of Tellinga

Houston entrepreneur has big plans for his art-driven, storytelling card company

bringing snail mail back

Alex Kurkowski can't count how many times he's gone looking for a greeting card — before some holiday, birthday, or special occasion — and found nothing that suited his recipient. He doesn't remember when he started editing them, either. For a few years now, he's been taking markers and pens to the greeting cards, blacking out words and scribbling new ones to say what he wanted to.

"They're templated. They're frozen, stagnant, fixed in what they are," Kurkowski says. "They suck."

But he can remember a few moments that changed that for him — and for Houston. When he started sending his family cards he'd sketched that depicted scenes from their lives, his classmates in the Rice University MBA program told him that, despite his pharmaceuticals background, this might actually be the right business for him.

Tellinga is hardly just a maker of greeting cards; it's in the business of storytelling, and customers can have personalized artworks delivered right to their mailboxes — a site for reclaiming, Kurkowski says, from the dread of bills and marketing materials.

"I'm trying to tap back into the tangible, physical and real side of life," Kurkowski says.

A year ago, Kurkowski sent his first Tellingas — short for "Telling a Story" — as an official business. He made the initial cards himself, but soon couldn't meet the demand on his own. Today, Tellingas are crafted from a cohort of more than 20 artists who are mostly Houston-based and, as Kurkowski says, make his work look like garbage.

Customers can select a few purchase options for customers, ranging from a one-panel story to 12 scenes. They upload a photo of the people they want drawn and submit their idea for the artwork on the website — they can create renderings of real-life events they want to remember or they might tell a wacky, fantasy story. For Kurkowski, the most important part is receiving the art over time — for example, the 12-panel pieces are sent over a one-month period.

Currently, Tellinga's only full-time staff is Kurkowski, but he's looking to hire a CTO to manage the growing demands of the website, where orders are placed. He also wants Tellinga to grow into the Airbnb model, with artists posting their works on his site and setting the price of their commissions themselves. Kurkoswki will be raising funds in the next investment round.

Until then, he's hoping to grow Tellinga's ability to turn stories into keepsakes — by offering ways to frame and preserve them, and by introducing a subscription model, so that customers can select days from of an entire calendar year to send their personalized artworks—constantly tapping back into that physical side of life like Kurkowsi wants.

"It's just cool because it's different," Kurkowski says. "It's getting away from the digital media world."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings